Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 16/20 | 0.86 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | OXTR | P30559 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5098355 | 0.93 | AVPR1A (0.86) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5095191 | 0.93 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL29500951 | 0.93 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2OXTR | |
| Hydrochloric Acid SCHEMBL5102018 | 0.92 | AVPR1A (0.98) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5108564 | 0.90 | AVPR1A (0.69) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5102014 | 0.88 | AVPR1A (0.89) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5108491 | 0.86 | AVPR1A (0.81) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5101519 | 0.85 | AVPR1A (0.80) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5282478 | 0.85 | AVPR1A (0.79) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL20727306 | 0.85 | AVPR1A (0.79) | AVPR1AAVPR2KCNH2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656183-B1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1597260-B1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | claimed |
| US-7119088-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | claimed |
| US-20060194794-A1 | Triazole compounds useful in therapy | PFIZER INC | 2006-08-31 | — | — | US | claimed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | claimed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442795-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1656183-B1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1597260-B1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-7119088-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060194794-A1 | Triazole compounds useful in therapy | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| US-20050026810-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2005-02-03 | — | — | US | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194794-A1 | Triazole compounds useful in therapy | CYP3A43, CYP3A5, CYP3A7 | AVPR1A 2844/4885AVPR2 1662/4885KCNH2 1889/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | AVPR1A 460/4885AVPR2 690/4885KCNH2 355/4885 |
| US-20050026810-A1 | Treatment of male sexual dysfunction | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885AVPR2 3/4885KCNH2 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.